Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Truist Financial Analyst Says

Quest Diagnostics (NYSE:DGX) had its target price hoisted by equities research analysts at Truist Financial from $225.00 to $250.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the medical research company’s stock. Truist Financial’s price target points to a potential upside of 9.62% from the company’s previous close.

DGX has been the topic of a number of other research reports. Robert W. Baird upped their target price on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research report on Thursday. Barclays lifted their price objective on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus price target of $231.73.

Quest Diagnostics Stock Performance

Shares of DGX opened at $228.05 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.08 and a current ratio of 1.59. The stock has a 50-day moving average of $203.23 and a two-hundred day moving average of $197.59. The stock has a market cap of $25.25 billion, a P/E ratio of 24.21, a P/E/G ratio of 2.61 and a beta of 0.58. Quest Diagnostics has a one year low of $165.78 and a one year high of $237.78.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, research analysts predict that Quest Diagnostics will post 11.17 EPS for the current year.

Insider Activity

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares in the company, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is owned by company insiders.

Hedge Funds Weigh In On Quest Diagnostics

Large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in Quest Diagnostics by 346.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock worth $4,329,000 after buying an additional 19,361 shares in the last quarter. Davis Selected Advisers lifted its position in shares of Quest Diagnostics by 16.8% in the fourth quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock valued at $275,895,000 after acquiring an additional 228,271 shares in the last quarter. Capital Management Associates Inc purchased a new position in shares of Quest Diagnostics in the fourth quarter valued at approximately $1,024,000. ANTIPODES PARTNERS Ltd boosted its stake in shares of Quest Diagnostics by 178.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock worth $29,847,000 after acquiring an additional 110,280 shares during the last quarter. Finally, Advisors Capital Management LLC boosted its stake in shares of Quest Diagnostics by 5.4% in the fourth quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock worth $54,460,000 after acquiring an additional 16,194 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.